is glp-1 insulin Mechanism of glucose-dependent, GLP1-potentiated secretion in GLP-1R and Diabetes

LDL, low-density lipoprotein

The gut microbiome generates a range of bioactive metabolites, including short-chain fatty acids (SCFAs) and secondary bile acids, which can act on enteroendocrine L cells via specific G-protein-coupled receptors, notably free fatty acid receptors 2 and 3 (FFAR2/3) and Takeda G-protein-coupled receptor 5 (TGR5)

However, many patients have been found to have residual gastric contents after fasting, even when on stable doses

The benefits of GLP-1 treatments are substantial

Improved glycaemic control and cardiometabolic markers (e.g., inflammatory lipids and blood pressure reported in readouts)